Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. 2026-10-23			5-day change	1st Jan Change
920.65 ^PKR	-0.07%		-1.21%	-9.96%

Aug. 27	Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
May. 18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	48,779	-	-
Change	-	11.36%	-9.96%	-	-
Enterprise Value (EV)	48,650	54,175	48,779	48,779	48,779
Change	-	11.36%	-9.96%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.6x	1.43x	1.27x
EV / Revenue	-	0x	1.6x	1.43x	1.27x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.89%	5.65%	6.52%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	920.65	920.65	920.65
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	3/26/25	4/7/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.89%	176M
ELI LILLY AND COMPANY	36.74x	13.1x	27.8x	0.54%	1,135B
JOHNSON & JOHNSON	38.61x	6.5x	18.29x	2.02%	636B
ABBVIE INC.	36.46x	8.38x	17.29x	2.41%	505B
ROCHE HOLDING AG	20.87x	5.11x	12.73x	2.56%	378B
MERCK & CO., INC.	105.89x	5.92x	25.41x	2.34%	358B
NOVARTIS AG	21.76x	5.67x	13.94x	2.81%	295B
ASTRAZENECA PLC	22.42x	4.53x	12.96x	1.95%	266B
AMGEN INC.	27.87x	7.16x	12.81x	2.3%	237B
GILEAD SCIENCES, INC.	-45.48x	6.98x	27.06x	2.11%	193B
Average	29.46x	7.04x	18.70x	2.39%	400.45B
Weighted average by Cap.	35.14x	8.29x	20.39x	1.8%